A novel, macrophage migration inhibitory factor suicide substrate inhibits motility and growth of lung cancer cells

作者：Winner Millicent; Meier Jason; Zierow Swen; Rendon Beatriz E; Crichlow Gregg V; Riggs Randall; Bucala Richard; Leng Lin; Smith Ned; Lolis Elias; Trent John O; Mitchell Robert A^*

来源：Cancer Research, 2008, 68(18): 7253-7257.

DOI：10.1158/0008-5472.CAN-07-6227

Although chemokine and growth factor receptors are attractive and popular targets for cancer therapeutic intervention, structure-based targeting of the ligands themselves is generally not considered practical. New evidence indicates that a notable exception to this is macrophage migration inhibitory factor (MIF). MIF, an autocrine- and paracrine-acting cytokine/growth factor, plays a pivotal role in both the initiation and maintenance of neoplastic diseases. MIF possesses a nonphysiologic enzymatic activity that is evolutionarily well-conserved. Although small molecule antagonists of MIFs enzymatic active site have been reported to inhibit biological activities of MIF, universally high IC(50)s have limited their clinical appeal. Using a computational virtual screening strategy, we have identified a unique small molecule inhibitor that serves as a suicide substrate for MIF, resulting in the covalent modification of the catalytically active NH2-terminal proline. Our studies further reveal that this compound, 4-iodo-6-phenylpyrimidine (4-IPP), is similar to 5 x to 10x times more potent in blocking MIF-dependent catalysis and lung adenocarcinoma cell migration and anchorage-independent growth than the prototypical MIF inhibitor, ISO-1. Finally, using an in silico combinatorial optimization strategy, we have identified four unique congeners of 4-IPP that. exhibit MIF inhibitory activity at concentrations 10x to 20x lower than that of parental 4-IPP.

• 出版日期2008-9-15